Immunome Inc expected to post a loss of 28 cents a share - Earnings Preview

Immunome

12/03/2024 12:54

* Immunome Inc  IMNM.OQ   IMNM.O  is expected to show a rise
in
quarterly revenue when it reports  results on March 14
(estimated) for the period ending December 31 2023
    * The Exton Pennsylvania-based  company is expected to
report
revenue of $2.069 million, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Immunome Inc is for a
loss
of 28 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "Strong Buy".​
    * Wall Street's median 12-month price target for Immunome
Inc is
$33.50​, above​ its last closing price of $23.65. ​​​

This summary was machine generated March 12 at 12:54 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)